aaa
Newsletter Pop-up

  • No products in the cart.

Reference na stranici: Silimarin/Silibin i kronična bolest jetre: višegodišnji brak

Reference na stranici: Silimarin/Silibin i kronična bolest jetre: višegodišnji brak

Autor/Izvor: Published online 2017 Jan 24. doi: 10.3390/molecules22020191 PMCID: PMC6155865

PMID: 28125040 Alessandro Federico,* Marcello Dallio, and Carmelina Loguercio

Tung-Hu Tsai, Academic Editor and Youngjin Jeon, Academic Editor

Author information Article notes Copyright and License information Disclaimer

Copyright © 2017 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

  1. Pradhan S.C., Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Ind. J. Med. Res. 2006;124:491–504. [PubMed] [Google Scholar]
  2. Schadewaldt H. The history of Silymarin. Contribution to the history of liver therapy. Die Med. Welt. 1969;20:902–914. [PubMed] [Google Scholar]
  3. Kim N.C., Graf T.N., Sparacino C.M., Wani M.C., Wall M.E. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum) Org. Biomol. Chem. 2003;1:1684–1689. doi: 10.1039/b300099k. [PubMed] [CrossRef] [Google Scholar]
  4. Loguercio C., Festi D. Silybin and the liver: From basic research to clinical practice. World J. Gastroenterol. 2011;17:2288–2301. doi: 10.3748/wjg.v17.i18.2288. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  5. Crocenzi F.A., Roma M.G. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr. Med. Chem. 2006;13:1055–1074. doi: 10.2174/092986706776360950. [PubMed] [CrossRef] [Google Scholar]
  6. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–2063. doi: 10.2165/00003495-200161140-00003. [PubMed] [CrossRef] [Google Scholar]
  7. Hawke R.L., Schrieber S.J., Soule T.A., Wen Z., Smith P.C., Reddy K.R., Wahed A.S., Belle S.H., Afdhal N.H., Navarro V.J., et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J. Clin. Pharmacol. 2010;50:434–449. doi: 10.1177/0091270009347475. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  8. Saller R., Melzer J., Reichling J., Brignoli R., Meier R. An updated systematic review of the pharmacology of silymarin. Forsch. Komplementmed. 2007;14:70–80. doi: 10.1159/000100581. [PubMed] [CrossRef] [Google Scholar]
  9. Barzaghi N., Crema F., Gatti G., Pifferi G., Perucca E. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur. J. Drug Metab. Pharmacokinet. 1990;15:333–338. doi: 10.1007/BF03190223. [PubMed] [CrossRef] [Google Scholar]
  10. Zarrelli A., Romanucci V., Tuccillo C., Federico A., Loguercio C., Gravante R., Di Fabio G. New silibinin glyco-conjugates: Synthesis and evaluation of antioxidant properties. Bioorg. Med. Chem. Lett. 2014;24:5147–5149. doi: 10.1016/j.bmcl.2014.10.023. [PubMed] [CrossRef] [Google Scholar]
  11. Dunnick J.K., Singh B., Nyska A., Peckham J., Kissling G.E., Sanders J.M. Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle. Toxicol. Pathol. 2011;39:398–409. doi: 10.1177/0192623310394211. [PubMed] [CrossRef] [Google Scholar]
  12. Saller R., Brignoli R., Melzer J., Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch. Komplementmed. 2008;15:9–20. doi: 10.1159/000113648. [PubMed] [CrossRef] [Google Scholar]
  13. Flaig T.W., Gustafson D.L., Su L.J., Zirrolli J.A., Crighton F., Harrison G.S., Pierson A.S., Agarwal R., Glode L.M. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investig. New Drugs. 2007;25:139–146. doi: 10.1007/s10637-006-9019-2. [PubMed] [CrossRef] [Google Scholar]
  14. Pliskova M., Vondracek J., Kren V., Gazak R., Sedmera P., Walterova D., Psotova J., Simanek V., Machala M. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology. 2005;215:80–89. doi: 10.1016/j.tox.2005.06.020. [PubMed] [CrossRef] [Google Scholar]
  15. Saliou C., Valacchi G., Rimbach G. Assessing bioflavonoids as regulators of NF-κB activity and inflammatory gene expression in mammalian cells. Meth. Enzymol. 2001;335:380–386. [PubMed] [Google Scholar]
  16. Polyak S.J., Morishima C., Lohmann V., Pal S., Lee D.Y., Liu Y., Graf T.N., Oberlies N.H. Identification of hepatoprotective flavonolignans from silymarin. Proc. Natl. Acad. Sci. USA. 2010;107:5995–5999. doi: 10.1073/pnas.0914009107. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  17. Yoo H.G., Jung S.N., Hwang Y.S., Park J.S., Kim M.H., Jeong M., Ahn S.J., Ahn B.W., Shin B.A., Park R.K., et al. Involvement of NF-κB and caspases in silibinin-induced apoptosis of endothelial cells. Int. J. Mol. Med. 2004;13:81–86. doi: 10.3892/ijmm.13.1.81. [PubMed] [CrossRef] [Google Scholar]
  18. Flora K., Hahn M., Rosen H., Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 1998;93:139–143. doi: 10.1111/j.1572-0241.1998.00139.x. [PubMed] [CrossRef] [Google Scholar]
  19. Kiruthiga P.V., Shafreen R.B., Pandian S.K., Arun S., Govindu S., Devi K.P. Protective effect of silymarin on erythrocyte haemolysate against benzo(a) pyrene and exogenous reactive oxygen species (H2O2) induced oxidative stress. Chemosphere. 2007;68:1511–1518. doi: 10.1016/j.chemosphere.2007.03.015. [PubMed] [CrossRef] [Google Scholar]
  20. Valenzuela A., Guerra R., Garrido A. Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis. Planta Med. 1987;53:402–405. doi: 10.1055/s-2006-962757. [PubMed] [CrossRef] [Google Scholar]
  21. Nencini C., Giorgi G., Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine. 2007;14:129–135. doi: 10.1016/j.phymed.2006.02.005. [PubMed] [CrossRef] [Google Scholar]
  22. Varzi H.N., Esmailzadeh S., Morovvati H., Avizeh R., Shahriari A., Givi M.E. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J. Vet. Pharmacol. Ther. 2007;30:477–481. doi: 10.1111/j.1365-2885.2007.00901.x. [PubMed] [CrossRef] [Google Scholar]
  23. Federico A., Dallio M., Di Fabio G., Zarrelli A., Zappavigna S., Stiuso P., Tuccillo C., Caraglia M., Loguercio C. Silybin-Phosphatidylcholine Complex Protects Human Gastric and Liver Cells from Oxidative Stress. In Vivo. 2015;29:569–575. [PubMed] [Google Scholar]
  24. Loguercio C., Federico A., Trappoliere M., Tuccillo C., de Sio I., Di Leva A., Niosi M., D’Auria M.V., Capasso R., Del Vecchio Blanco C., et al. The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: A pilot study. Dig. Dis. Sci. 2007;52:2387–2395. doi: 10.1007/s10620-006-9703-2. [PubMed] [CrossRef] [Google Scholar]
  25. Tyagi A., Agarwal C., Agarwal R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: Role in prostate cancer prevention. Mol. Cancer Ther. 2002;1:525–532. [PubMed] [Google Scholar]
  26. Yao J., Zhi M., Gao X., Hu P., Li C., Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz. J. Med. Biol. Res. 2013;46:270–277. doi: 10.1590/1414-431X20122551. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  27. Li H.B., Yang Y.R., Mo Z.J., Ding Y., Jiang W.J. Silibinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3K/Akt pathway inhibition. Braz. J. Med. Biol. Res. 2015;48:440–446. doi: 10.1590/1414-431X20144238. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  28. Federico A., Trappoliere M., Tuccillo C., de Sio I., Di Leva A., Del Vecchio Blanco C., Loguercio C. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: Preliminary observations. Gut. 2006;55:901–902. doi: 10.1136/gut.2006.091967. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  29. Krena V., Walterov D. Silybin and silymarin—New effects and applications. Biomed. Pap. 2005;149:29–41. doi: 10.5507/bp.2005.002. [PubMed] [CrossRef] [Google Scholar]
  30. Zhang S.H., Morris M.E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther. 2003;304:1258–1267. doi: 10.1124/jpet.102.044412. [PubMed] [CrossRef] [Google Scholar]
  31. Zhang S.Z., Morris M.E. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm. Res. 2003;20:1184–1191. doi: 10.1023/A:1025044913766. [PubMed] [CrossRef] [Google Scholar]
  32. Nguyen H., Zhang S.Z., Morris M.E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci. 2002;92:250–257. doi: 10.1002/jps.10283. [PubMed] [CrossRef] [Google Scholar]
  33. Sinnberg T., Menzel M., Kaesler S., Biedermann T., Sauer B., Nahnsen S., Schwarz M., Garbe C., Schittek B. Suppression of casein kinase 1α in melanoma cells induces a switch in β-catenin signaling to promote metastasis. Cancer Res. 2010;70:6999–7009. doi: 10.1158/0008-5472.CAN-10-0645. [PubMed] [CrossRef] [Google Scholar]
  34. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer. 2008;8:387–398. doi: 10.1038/nrc2389. [PubMed] [CrossRef] [Google Scholar]
  35. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., He X. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837–847. doi: 10.1016/S0092-8674(02)00685-2. [PubMed] [CrossRef] [Google Scholar]
  36. Hart M., Concordet J.P., Lassot I., Albert I., del los Santos R., Durand H., Perret C., Rubinfeld B., Margottin F., Benarous R., et al. The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr. Biol. 1999;9:207–210. doi: 10.1016/S0960-9822(99)80091-8. [PubMed] [CrossRef] [Google Scholar]
  37. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol. 2000;60:1051–10591. doi: 10.1016/S0006-2952(00)00385-3. [PubMed] [CrossRef] [Google Scholar]
  38. Wang J.Y., Chang C.C., Chiang C.C., Chen W.M., Hung S.C. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J. Cell. Biochem. 2012;113:1733–1743. doi: 10.1002/jcb.24043. [PubMed] [CrossRef] [Google Scholar]
  39. Singh R.P., Agarwal R. Prostate cancer prevention by silibinin. Curr. Cancer Drug Targets. 2004;4:1–11. doi: 10.2174/1568009043481605. [PubMed] [CrossRef] [Google Scholar]
  40. Pferschy-Wenzig E.M., Atanasov A.G., Malainer C., Noha S.M., Kunert O., Schuster D., Heiss E.H., Oberlies N.H., Wagner H., Bauer R., et al. Identification of Isosilybin A from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J. Nat. Prod. 2014;77:842–847. doi: 10.1021/np400943b. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  41. Trappoliere M., Caligiuri A., Schmid M., Bertolani C., Failli P., Vizzutti F., Novo E., di Manzano C., Marra F., Loguercio C., et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J. Hepatol. 2009;50:1102–1111. doi: 10.1016/j.jhep.2009.02.023. [PubMed] [CrossRef] [Google Scholar]
  42. Favari L., Perez-Alvarez V. Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats. Arch. Med. Res. 1997;28:11–17. [PubMed] [Google Scholar]
  43. Boigk G., Stroedter L., Herbst H., Waldschmidt J., Riecken E.O., Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997;26:643–649. doi: 10.1002/hep.510260316. [PubMed] [CrossRef] [Google Scholar]
  44. Jia J.D., Bauer M., Cho J.J., Ruehl M., Milani S., Boigk G., Riecken E.O., Schuppan D. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by down-regulation of procollagen α1(I) and TIMP-1. J. Hepatol. 2001;35:392–398. doi: 10.1016/S0168-8278(01)00148-9. [PubMed] [CrossRef] [Google Scholar]
  45. Lieber C.S., Leo M.A., Cao Q., Ren C., De Carli L.M. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J. Clin. Gastroenterol. 2003;37:336–339. doi: 10.1097/00004836-200310000-00013. [PubMed] [CrossRef] [Google Scholar]
  46. Neha, Jaggi A.S., Singh N. Silymarin and Its Role in Chronic Diseases. Adv. Exp. Med. Biol. 2016;929:25–44. [PubMed] [Google Scholar]
  47. Mayer K.E., Myers R.P., Lee S.S. Silymarin treatment of viral hepatitis: A systematic review. J. Viral Hepat. 2005;12:559–567. doi: 10.1111/j.1365-2893.2005.00636.x. [PubMed] [CrossRef] [Google Scholar]
  48. Haddad Y., Vallerand D., Brault A., Haddad P.S. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid.-Based Complement. Altern. Med. 2011;2011:647903. doi: 10.1093/ecam/nep164. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  49. Colturato C.P., Constantin R.P., Maeda A.S., Jr., Constantin R.P., Yamamoto N.S., Bracht A., Ishii-Iwamoto E.L., Constantin J. Metabolic effects of silibinin in the rat liver. Chem. Biol. Interact. 2012;195:119–132. doi: 10.1016/j.cbi.2011.11.006. [PubMed] [CrossRef] [Google Scholar]
  50. Meeran S.M., Katiyar S., Elmets C.A., Katiyar S.K. Silymarin inhibits UV radiation induced immunosuppression through augmentation of interleukin-12 in mice. Mol. Cancer Ther. 2006;7:1660–1668. doi: 10.1158/1535-7163.MCT-06-0095. [PubMed] [CrossRef] [Google Scholar]
  51. Bhattacharya S. Milk thistle (Silybum marianum L. Gaert.) seeds in health. In: Preedy V.R., Watson R.R., Patel V., editors. Nuts and Seeds in Health and Disease Prevention. 1st ed. Academic Press; London, UK: Burlington, VT, USA: San Diego, CA, USA: 2011. pp. 759–766. Chapter 90. [Google Scholar]
  52. Kreeman V., Skottova N., Walterova D. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med. 1998;64:138–142. doi: 10.1055/s-2006-957391. [PubMed] [CrossRef] [Google Scholar]
  53. Tyagi A., Agarwal C., Harrison G., Glode L.M., Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004;25:1711–1720. doi: 10.1093/carcin/bgh180. [PubMed] [CrossRef] [Google Scholar]
  54. Das S., Roy P., Auddy R.G., Mukherjee A. Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity. Int. J. Nanomed. 2011;6:1291–1301. [PMC free article] [PubMed] [Google Scholar]
  55. Jain A., Yadav A., Bozhkov A.I., Padalko V.I., Flora S.J. Therapeutic efficacy of sylimarin and naringenin in reducing arsenic-induced hepatic damage in young rats. Ecotoxicol. Environ. Saf. 2011;74:607–614. doi: 10.1016/j.ecoenv.2010.08.002. [PubMed] [CrossRef] [Google Scholar]
  56. Mohamed O., Salam E.A., Saleem A.A., Shafee N. Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin on carbon tetrachloride-induced hepatic injury in rats. Inflammopharmacology. 2010;18:87–94. [PubMed] [Google Scholar]
  57. Sharma Y., Agarwal C., Singh A.K., Agarwal R. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol. Carcinog. 2001;30:224–236. doi: 10.1002/mc.1032. [PubMed] [CrossRef] [Google Scholar]
  58. Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., Jeng K.C. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. Neurosci. 2002;16:2103–2112. doi: 10.1046/j.1460-9568.2002.02290.x. [PubMed] [CrossRef] [Google Scholar]
  59. Sayyah M., Boostani H., Pakseresht S., Malayeri A. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog. Neuro-Psychopharm. Biol. Psychiatry. 2010;34:362–365. doi: 10.1016/j.pnpbp.2009.12.016. [PubMed] [CrossRef] [Google Scholar]
  60. Wood N.J. Liver: Nonobese individuals in the developing world are at risk of nonalcoholic fatty liver and liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010;7:357. doi: 10.1038/nrgastro.2010.95. [PubMed] [CrossRef] [Google Scholar]
  61. Hackett E.S., Twedt D.C., Gustafson D.L. Milk thistle and its derivative compounds: A review of opportunities for treatment of liver disease. J. Vet. Intern. Med. 2013;27:10–16. doi: 10.1111/jvim.12002. [PubMed] [CrossRef] [Google Scholar]
  62. Charlton M. Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin. Gastroenterol. Hepatol. 2004;2:1048–1058. doi: 10.1016/S1542-3565(04)00440-9. [PubMed] [CrossRef] [Google Scholar]
  63. Lozano-Sepulveda S.A., Bryan-Marrugo O.L., Cordova-Fletes C., Gutierrez-Ruiz M.C., Rivas-Estilla A.M. Oxidative stress modulation in hepatitis C virus infected cells. World J. Hepatol. 2015;7:2880–2889. doi: 10.4254/wjh.v7.i29.2880. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  64. Wei F., Liu S.K., Liu X.Y., Li Z.J., Li B., Zhou Y.L., Zhang H.Y., Li Y.W. Meta-analysis: Silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur. J. Clin. Microbiol. Infect. Dis. 2013;32:657–669. doi: 10.1007/s10096-012-1789-1. [PubMed] [CrossRef] [Google Scholar]
  65. Petruzziello A., Marigliano S., Loquercio G., Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: An epidemiological up-date in Europe. Infect. Agents Cancer. 2016;11:53. doi: 10.1186/s13027-016-0099-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  66. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335–1374. doi: 10.1002/hep.22759. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  67. Yang Z., Zhuang L., Lu Y., Xu Q., Chen X. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: A meta-analysis of randomized controlled trials. Biomed. Res. Int. 2014;2014:941085. doi: 10.1155/2014/941085. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  68. Blaising J., Lévy P.L., Gondeau C., Phelip C., Varbanov M., Teissier E., Ruggiero F., Polyak S.J., Oberlies N.H., Ivanovic T., et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell. Microbiol. 2013;15:1866–1882. doi: 10.1111/cmi.12155. [PubMed] [CrossRef] [Google Scholar]
  69. Wagoner J., Negash A., Kane O.J., Martinez L.E., Nahmias Y., Bourne N., Owen D.M., Grove J., Brimacombe C., McKeating J.A., et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010;51:1912–1921. doi: 10.1002/hep.23587. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  70. Wagoner J., Morishima C., Graf T.N., Oberlies N.H., Teissier E., Pécheur E.I., Tavis J.E., Polyak S.J. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS ONE. 2011;6:e16464. doi: 10.1371/journal.pone.0016464. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  71. Ahmed-Belkacem A., Ahnou N., Barbotte L., Wychowski C., Pallier C., Brillet R., Pohl R.T., Pawlotsky J.M. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2010;138:1112–1122. doi: 10.1053/j.gastro.2009.11.053. [PubMed] [CrossRef] [Google Scholar]
  72. Guedj J., Dahari H., Pohl R.T., Ferenci P., Perelson A.S. Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J. Hepatol. 2012;56:1019–1024. doi: 10.1016/j.jhep.2011.12.012. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  73. Ferenci P., Scherzer T.M., Kerschner H., Rutter K., Beinhardt S., Hofer H., Schöniger-Hekele M., Holzmann H., Steindl-Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561–1567. doi: 10.1053/j.gastro.2008.07.072. [PubMed] [CrossRef] [Google Scholar]
  74. Dahari H., Shteingart S., Gafanovich I., Cotler S.J., D’Amato M., Pohl R.T., Weiss G., Ashkenazi Y.J., Tichler T., Goldin E., et al. Sustained virological response with intravenous silibinin: Individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver Int. 2015;35:289–294. doi: 10.1111/liv.12692. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  75. Rutter K., Scherzer T.M., Beinhardt S., Kerschner H., Stattermayer A.F., Hofer H., Popow-Kraupp T., Steindl-Munda P., Ferenci P. Intravenous silibinin as “rescue treatment” for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antivir. Ther. 2011;16:1327–1333. doi: 10.3851/IMP1942. [PubMed] [CrossRef] [Google Scholar]
  76. Neumann U.P., Biermer M., Eurich D., Neuhaus P., Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin monotherapy. J. Hepatol. 2010;52:951–952. doi: 10.1016/j.jhep.2010.02.002. [PubMed] [CrossRef] [Google Scholar]
  77. Goossens N., Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403–2412. doi: 10.1002/hep.26905. [PubMed] [CrossRef] [Google Scholar]
  78. Braun D.L., Rauch A., Aouri M., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., Müllhaupt B., Metzner K.J., Decosterd L., et al. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PLoS ONE. 2015;10:e0133028. doi: 10.1371/journal.pone.0133028. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  79. Hezode C., Fontaine H., Dorival C., Zoulim F., Larrey D., Canva V., de Ledinghen V., Poynard T., Samuel D., Bourliere M., et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147:132–142.e4. doi: 10.1053/j.gastro.2014.03.051. [PubMed] [CrossRef] [Google Scholar]
  80. De Meyer S., Dierynck I., Ghys A., Beumont M., Daems B., Van Baelen B., Sullivan J.C., Bartels D.J., Kieffer T.L., Zeuzem S., et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial. Hepatology. 2012;56:2106–2115. doi: 10.1002/hep.25962. [PubMed] [CrossRef] [Google Scholar]
  81. Federico A., Dallio M., Ormando V.M., Abenavoli L., Masarone M., Persico M., Loguercio C. Alcoholic Liver Disease and Hepatitis C Chronic Infection. Rev. Recent Clin. Trials. 2016;11:201–207. doi: 10.2174/1574887111666160126144940. [PubMed] [CrossRef] [Google Scholar]
  82. Galicia-Moreno M., Gutiérrez-Reyes G. The role of oxidative stress in the development of alcoholic liver disease. Rev. Gastroenterol. Mex. 2014;79:135–144. doi: 10.1016/j.rgmxen.2014.06.007. [PubMed] [CrossRef] [Google Scholar]
  83. Yeh M.M., Brunt E.M. Pathological features of fatty liver disease. Gastroenterology. 2014;147:754–764. doi: 10.1053/j.gastro.2014.07.056. [PubMed] [CrossRef] [Google Scholar]
  84. Song Z., Deaciuc I., Song M., Lee D.Y., Liu Y., Ji X., McClain C. Silymarin protects against acute ethanol-induced hepatotoxicity in mice. Alcohol. Clin. Exp. Res. 2006;30:407–413. doi: 10.1111/j.1530-0277.2006.00063.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  85. Das S.K., Mukherjee S. Biochemical and immunological basis of silymarin effect, a milk thistle (Silybum marianum) against ethanol-induced oxidative damage. Toxicol. Mech. Methods. 2012;22:409–413. doi: 10.3109/15376516.2012.673090. [PubMed] [CrossRef] [Google Scholar]
  86. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–795. doi: 10.1038/nature05292. [PubMed] [CrossRef] [Google Scholar]
  87. Sekine S., Ichijo H. Mitochondrial proteolysis: Its emerging roles in stress responses. Biochim. Biophys. Acta. 2015;1850:274–280. doi: 10.1016/j.bbagen.2014.10.012. [PubMed] [CrossRef] [Google Scholar]
  88. Rolo A.P., Oliveira P.J., Moreno A.J., Palmeira C.M. Protection against post-ischemic mitochondrial injury in rat liver by silymarin or TUDC. Hepatol. Res. 2003;26:217–224. doi: 10.1016/S1386-6346(03)00108-6. [PubMed] [CrossRef] [Google Scholar]
  89. Detaille D., Sanchez C., Sanz N., Lopez-Novoa J.M., Leverve X., El-Mir M.Y. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci. 2008;82:1070–1076. doi: 10.1016/j.lfs.2008.03.007. [PubMed] [CrossRef] [Google Scholar]
  90. Grattagliano I., Diogo C.V., Mastrodonato M., de Bari O., Persichella M., Wang D.Q., Liquori A., Ferri D., Carratù M.R., Oliveira P.J., et al. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. World J. Gastroenterol. 2013;19:3007–3017. doi: 10.3748/wjg.v19.i20.3007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  91. Mazzio E.A., Harris N., Soliman K.F. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Plant Med. 1998;64:603–606. doi: 10.1055/s-2006-957530. [PubMed] [CrossRef] [Google Scholar]
  92. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. doi: 10.1002/hep.25762. [PubMed] [CrossRef] [Google Scholar]
  93. Charlton M.R., Burns J.M., Pedersen R.A., Watt K.D., Heimbach J.K., Dierkhising R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253. doi: 10.1053/j.gastro.2011.06.061. [PubMed] [CrossRef] [Google Scholar]
  94. Younossi Z.M., Otgonsuren M., Henry L., Venkatesan C., Mishra A., Erario M., Hunt S. Association of non-alcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723–1730. doi: 10.1002/hep.28123. [PubMed] [CrossRef] [Google Scholar]
  95. Starley B.Q., Calcagno C.J., Harrison S.A. Non-alcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 2010;51:1820–1832. doi: 10.1002/hep.23594. [PubMed] [CrossRef] [Google Scholar]
  96. Yasui K., Hashimoto E., Komorizono Y., Koike K., Arii S., Imai Y., Shima T., Kanbara Y., Saibara T., Mori T., et al. Characteristics of patients with non-alcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2011;9:428–433. doi: 10.1016/j.cgh.2011.01.023. [PubMed] [CrossRef] [Google Scholar]
  97. Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism. 2016;65:1038–1048. doi: 10.1016/j.metabol.2015.12.012. [PubMed] [CrossRef] [Google Scholar]
  98. Stefan N., Kantartzis K., Haring H.U. Causes and metabolic consequences of fatty liver. Endocr. Rev. 2008;29:939–960. doi: 10.1210/er.2008-0009. [PubMed] [CrossRef] [Google Scholar]
  99. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., Shoelson S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 2005;11:183–190. doi: 10.1038/nm1166. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  100. Younossi Z.M., Otgonsuren M., Venkatesan C., Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013;62:352–360. doi: 10.1016/j.metabol.2012.08.005. [PubMed] [CrossRef] [Google Scholar]
  101. Hossain N., Afendy A., Stepanova M., Nader F., Srishord M., Rafiq N., Goodman Z., Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009;7:1224–1229. doi: 10.1016/j.cgh.2009.06.007. [PubMed] [CrossRef] [Google Scholar]
  102. Reddy S.K., Steel J.L., Chen H.W., Demateo D.J., Cardinal J., Behari J., Humar A., Marsh J.W., Geller D.A., Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809–1819. doi: 10.1002/hep.25536. [PubMed] [CrossRef] [Google Scholar]
  103. Federico A., Dallio M., Godos J., Loguercio C., Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: Translational and clinical evidence. Transl. Res. 2016;167:116–124. doi: 10.1016/j.trsl.2015.08.002. [PubMed] [CrossRef] [Google Scholar]
  104. Miele L., Forgione A., Hernandez A.P., Gabrieli M.L., Vero V., Di Rocco P., Greco A.V., Gasbarrini G., Gasbarrini A., Grieco A. The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. Eur. Rev. Med. Pharmacol. Sci. 2005;9:273–277. [PubMed] [Google Scholar]
  105. Anderson N., Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 2008;60:311–357. doi: 10.1124/pr.108.00001. [PubMed] [CrossRef] [Google Scholar]
  106. Trappoliere M., Tuccillo C., Federico A., Di Leva A., Niosi M., D’Alessio C., Capasso R., Coppola F., Dauria M., Loguercio C. The treatment of NAFLD. Eur. Rev. Med. Pharmacol. Sci. 2005;9:299–304. [PubMed] [Google Scholar]
  107. Masarone M., Federico A., Abenavoli L., Loguercio C., Persico M. Non alcoholic fatty liver: Epidemiology and natural history. Rev. Recent Clin. Trials. 2014;9:126–133. doi: 10.2174/1574887109666141216111143. [PubMed] [CrossRef] [Google Scholar]
  108. Nobili V., Svegliati-Baroni G., Alisi A., Miele L., Valenti L., Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. J. Hepatol. 2013;58:1218–1229. doi: 10.1016/j.jhep.2012.12.003. [PubMed] [CrossRef] [Google Scholar]
  109. Byrne C.D., Targher G. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64:1388–1402. [PubMed] [Google Scholar]
  110. Godos J., Federico A., Dallio M., Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: Molecular mechanisms of protection. Int. J. Food Sci. Nutr. 2016;2:1–10. doi: 10.1080/09637486.2016.1221900. [PubMed] [CrossRef] [Google Scholar]
  111. Christodoulou E., Kechagia I.A., Tzimas S., Balafas E., Kostomitsopoulos N., Archontaki H., Dokoumetzidis A., Valsami G. Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP-β-CD lyophilized product. Int. J. Pharm. 2015;493:366–373. doi: 10.1016/j.ijpharm.2015.07.060. [PubMed] [CrossRef] [Google Scholar]
  112. Huang S., Czech M.P. The GLUT4 glucose transporter. Cell Metab. 2007;5:237–252. doi: 10.1016/j.cmet.2007.03.006. [PubMed] [CrossRef] [Google Scholar]
  113. Hotamisligil G.S. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int. J. Obes. 2008;32:S52–S54. doi: 10.1038/ijo.2008.238. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  114. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333–336. doi: 10.1038/nature01137. [PubMed] [CrossRef] [Google Scholar]
  115. Loguercio C., Andreone P., Brisc C., Brisc M.C., Bugianesi E., Chiaramonte M., Cursaro C., Danila M., de Sio I., Floreani A., et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic. Biol. Med. 2012;52:1658–1665. doi: 10.1016/j.freeradbiomed.2012.02.008. [PubMed] [CrossRef] [Google Scholar]
  116. Stiuso P., Scognamiglio I., Murolo M., Ferranti P., De Simone C., Rizzo M.R., Tuccillo C., Caraglia M., Loguercio C., Federico A. Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: A pilot study. Oxid. Med. Cell. Longev. 2014;2014:169216. doi: 10.1155/2014/169216. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  117. Ni X., Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD) Am. J. Transl. Res. 2016;8:1073–1081. [PMC free article] [PubMed] [Google Scholar]
  118. Pruszczynski A. Histogenesis and pathological anatomy of liver cirrhosis. Pol. Arch. Med. Wewn. 1962;32:1379–1388. [PubMed] [Google Scholar]
  119. Bataller R., Schwabe R.F., Choi Y.H., Yang L., Paik Y.H., Lindquist J., Qian T., Schoonhoven R., Hagedorn C.H., Lemasters J.J., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Investig. 2003;112:1383–1394. doi: 10.1172/JCI18212. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  120. Clichici S., Olteanu D., Nagy A.L., Oros A., Filip A., Mircea P.A. Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl4-treated rats. J. Med. Food. 2015;18:290–298. doi: 10.1089/jmf.2013.0179. [PubMed] [CrossRef] [Google Scholar]
  121. Karidis N.P., Kouraklis G., Theocharis S.E. Platelet-activating factor in liver injury: A relational scope. World J. Gastroenterol. 2006;12:3695–3706. doi: 10.3748/wjg.v12.i23.3695. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  122. Karantonis H.C., Gribilas G., Stamoulis I., Giaginis C., Spiliopoulou C., Kouraklis G., Demopoulos C., Theocharis S.E. Platelet-activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis. Dig. Dis. Sci. 2010;55:276–284. doi: 10.1007/s10620-009-0745-0. [PubMed] [CrossRef] [Google Scholar]
  123. Lu Y.Y., Wang C.P., Zhou L., Chen Y., Su S.H., Feng Y.Y., Yang Y.P. Synthesis of platelet-activating factor and its receptor expression in Kupffer cells in rat carbon tetrachloride-induced cirrhosis. World J. Gastroenterol. 2008;14:764–770. doi: 10.3748/wjg.14.764. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  124. Yang Y., Nemoto E.M., Harvey S.A., Subbotin V.M., Gandhi C.R. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut. 2004;53:877–883. doi: 10.1136/gut.2003.024893. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  125. Stanca E., Serviddio G., Bellanti F., Vendemiale G., Siculella L., Giudetti A.M. Down-regulation of LPCAT expression increases platelet-activating factor level in cirrhotic rat liver: Potential antiinflammatory effect of silybin. Biochim. Biophys. Acta. 2013;1832:2019–2026. doi: 10.1016/j.bbadis.2013.07.005. [PubMed] [CrossRef] [Google Scholar]
  126. Serviddio G., Pereda J., Pallardó F.V., Carretero J., Borras C., Cutrin J., Vendemiale G., Poli G., Viña J., Sastre J. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology. 2004;39:711–720. doi: 10.1002/hep.20101. [PubMed] [CrossRef] [Google Scholar]
  127. Arduini A., Serviddio G., Tormos A.M., Monsalve M., Sastre J. Mitochondrial dysfunction in cholestatic liver diseases. Front. Biosci. 2012;4:2233–2252. doi: 10.2741/e539. [PubMed] [CrossRef] [Google Scholar]
  128. Serviddio G., Bellanti F., Stanca E., Lunetti P., Blonda M., Tamborra R., Siculella L., Vendemiale G., Capobianco L., Giudetti A.M. Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radic. Biol. Med. 2014;73:117–126. doi: 10.1016/j.freeradbiomed.2014.05.002. [PubMed] [CrossRef] [Google Scholar]
  129. Muriel P., Moreno M.G., Hernández Mdel C., Chávez E., Alcantar L.K. Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: Effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin. Pharmacol. Toxicol. 2005;96:375–380. doi: 10.1111/j.1742-7843.2005.pto_06.x. [PubMed] [CrossRef] [Google Scholar]
  130. Prasad V., Goldstein J.A. US news and world report cancer hospital rankings: Do they reflect measures of research productivity? PLoS ONE. 2014;9:e107803. doi: 10.1371/journal.pone.0107803. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  131. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008;359:378–390. doi: 10.1056/NEJMoa0708857. [PubMed] [CrossRef] [Google Scholar]
  132. Gopalakrishnan R., Sundaram J., Sattu K., Pandi A., Thiruvengadam D. Dietary supplementation of silymarin is associated with decreased cell proliferation, increased apoptosis, and activation of detoxification system in hepatocellular carcinoma. Mol. Cell. Biochem. 2013;377:163–176. doi: 10.1007/s11010-013-1582-1. [PubMed] [CrossRef] [Google Scholar]
  133. Stoimenov I., Helleday T. PCNA on the crossroad of cancer. Biochem. Soc. Trans. 2009;37:605–613. doi: 10.1042/BST0370605. [PubMed] [CrossRef] [Google Scholar]
  134. Borzio M., Trere D., Borzio F., Ferrari A.R., Bruno S., Roncalli M., Colloredo G., Leandro G., Oliveri F., Derenzini M. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol. Pathol. 1998;51:96–101. doi: 10.1136/mp.51.2.96. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  135. Senthilnathan P., Padmavathi R., Magesh V., Sakthisekaran D. Chemotherapeutic efficacy of paclitaxel in combination with Withania somnifera on benzo(a)pyrene-induced experimental lung cancer. Cancer Sci. 2006;97:658–664. doi: 10.1111/j.1349-7006.2006.00224.x. [PubMed] [CrossRef] [Google Scholar]
  136. Goldhirsch A., Berger E., Muller O., Maibach R., Misteli S., Buser K., Roesler H., Brunner K. Ovarian cancer and tumor markers: Sialic acid, galactosyltransferase and CA-125. Oncology. 1988;45:281–286. doi: 10.1159/000226623. [PubMed] [CrossRef] [Google Scholar]
  137. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J. Pathol. 1996;179:358–369. doi: 10.1002/(SICI)1096-9896(199608)179:4<358::AID-PATH564>3.0.CO;2-T. [PubMed] [CrossRef] [Google Scholar]
  138. Manoharan S., Padmanabhan M., Kolanjiappan K., Ramachandran C.R., Suresh K. Analysis of glycoconjugates in patients with oral squamous cell carcinoma. Clin. Chim. Acta. 2004;339:91–96. doi: 10.1016/j.cccn.2003.09.006. [PubMed] [CrossRef] [Google Scholar]
  139. Joo M., Lee H.K., Kang Y.K. Expression of beta-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression. J. Korean Med. Sci. 2003;18:211–217. doi: 10.3346/jkms.2003.18.2.211. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  140. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer. 2003;3:46–54. doi: 10.1038/nrc968. [PubMed] [CrossRef] [Google Scholar]
  141. Lah J.J., Cui W., Hu K.Q. Effects and mechanisms of silibinin on human hepatoma cell lines. World J. Gastroenterol. 2007;13:5299–5305. doi: 10.3748/wjg.v13.i40.5299. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  142. Xu J., You C., Zhang S., Huang S., Cai B., Wu Z., Li H. Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice. J. Neurosurg. 2006;105:306–310. doi: 10.3171/ped.2006.105.4.306. [PubMed] [CrossRef] [Google Scholar]
  143. Tutton M.G., George M.L., Eccles S.A., Burton S., Swift R.I., Abula A.M. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int. J. Cancer. 2003;107:541–550. doi: 10.1002/ijc.11436. [PubMed] [CrossRef] [Google Scholar]
  144. Momeny M., Khorramizadeh M.R., Ghaffari S.H., Yousefi M., Yekaninejad M.S., Esmaeili R., Jahanshiri Z., Nooridaloii M.R. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur. J. Pharmacol. 2008;591:13–20. doi: 10.1016/j.ejphar.2008.06.011. [PubMed] [CrossRef] [Google Scholar]
You don't have permission to register